SFRP2 and breast cancer: Epigenetic silencing of WNT/β‐CATENIN antagonists is frequently observed in breast cancer, and reduced expression of APC, CDH1, SFRP1 and SFRP2 due to promoter hypermethylation has been reported in many breast tumours.49, 50